Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging

University of British Columbia

$50,000.00

Effect of imatinib mesylate (Glivec) on sarcopenia-associated fibrofatty muscle degeneration

EF 2010-11

Résumé
With the predicted increase of the elderly population, Canada's health care industry is set to face a higher demand for therapies aimed at treating aging-related disorders in the near future. Sarcopenia is a degenerative process characterized by the replacement of skeletal muscle by fibrofatty scar during aging which leads to loss of muscle integrity and strength. Our laboratory has recently identified a population of progenitor cells that expand upon muscle damage and can either facilitate muscle regeneration or generate the scar that interferes with muscle function. These cells are termed fibro/adipogencic progenitors (FAPs) given their capacity to generate both fat and fibrous tissue. One important characteristic of FAPs is their ability to respond to platelet-derived growth (PDGF), a factor also used by cancer cells to proliferate. We hypothesize that inhibition of this receptor using Glivec (Novartis), a commercially available drug already routinely used in patients, could prevent the aberrant scar formation observed in the aged muscle.
Programme
Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
228783
Name
Rossi Fabio M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Institute of Aging Pilot Projects
Projecttitle
Effect of imatinib mesylate (Glivec) on sarcopenia-associated fibrofatty muscle degeneration
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Pilot Projects in Aging - Biological & Clinical Aspects of Aging
Keyworddelim
Imatinib Mesylate; Muscle Regeneration; Sarcopenia; Stem Cells
Abstract
With the predicted increase of the elderly population, Canada's health care industry is set to face a higher demand for therapies aimed at treating aging-related disorders in the near future. Sarcopenia is a degenerative process characterized by the replacement of skeletal muscle by fibrofatty scar during aging which leads to loss of muscle integrity and strength. Our laboratory has recently identified a population of progenitor cells that expand upon muscle damage and can either facilitate muscle regeneration or generate the scar that interferes with muscle function. These cells are termed fibro/adipogencic progenitors (FAPs) given their capacity to generate both fat and fibrous tissue. One important characteristic of FAPs is their ability to respond to platelet-derived growth (PDGF), a factor also used by cancer cells to proliferate. We hypothesize that inhibition of this receptor using Glivec (Novartis), a commercially available drug already routinely used in patients, could prevent the aberrant scar formation observed in the aged muscle.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rossi, Fabio M
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Aging~ $50,000~ $0~